These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129 [Abstract] [Full Text] [Related]
7. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Bruckert E, De Gennes JL, Malbecq W, Baigts F. Clin Cardiol; 1995 Nov 15; 18(11):621-9. PubMed ID: 8590530 [Abstract] [Full Text] [Related]
10. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. J Am Coll Cardiol; 2006 Jul 18; 48(2):396-401. PubMed ID: 16843192 [Abstract] [Full Text] [Related]
11. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. Ihm SH, Chung WB, Lee JM, Hwang BH, Yoo KD, Her SH, Song WH, Chae IH, Park TH, Kim JH, Jeon DW, Cho BR, Kang SH, Park SD, Lee JB, Woo JT, Lee BW, Han KA, Won KH, Kim HS, Yu JM, Chung CH, Kim HJ, Cho HC, Seung KB. Clin Ther; 2020 Oct 18; 42(10):2021-2035.e3. PubMed ID: 32891418 [Abstract] [Full Text] [Related]
16. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK. Atherosclerosis; 2007 Jan 18; 190(1):205-11. PubMed ID: 16500662 [Abstract] [Full Text] [Related]
17. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Am J Cardiovasc Drugs; 2010 Jan 18; 10(2):73-84. PubMed ID: 20136164 [Abstract] [Full Text] [Related]